[ad_1] In pharma, you can take a larger slice of the healthcare pie than your peers, but you are still constrained by the size of the pie. No matter how…
Tag: ABBV
$19 Billion in a Week: AbbVie Makes Two Big Bets
[ad_1] Early last week, AbbVie was on every healthcare investment banker’s list. But with two quick deal announcements under its belt in just six days, AbbVie may have transformed its…
The Big Pharma Stock Trade: Weight Loss Is In, Covid-19 Is Out
[ad_1] What to Read Next [ad_2] Source link
Even Mark Cuban Can’t Fix This Broken Drug System
[ad_1] Coherus BioSciences’ partnership to offer deeply discounted biosimilar Humira can go only so far in reducing overall prices. [ad_2] Source link
The End of AbbVie’s $200 Billion Monopoly Won’t Sink the Stock
[ad_1] The drugmaker is offering steep discounts on its immune-disease therapy Humira to protect market share this year. [ad_2] Source link
WSJ News Exclusive | AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira
[ad_1] Drugmaker AbbVie Inc. is looking for its next hit. Now that its blockbuster immune-disease therapy Humira is facing lower priced competition, AbbVie is turning to a pair of next-generation…
Drugmakers Raise Prices on Nearly 1,000 Medicines but Show Restraint
[ad_1] Health List prices climb by 5.6% on average as new federal law aims to lower drug costs [ad_2] Source link
A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them.
[ad_1] Pharmaceutical companies could try to blunt the limits on future price increases. [ad_2] Source link